Efficacy, safety and medication cost implications of adalimumab 40 mg weekly dosing in patients with psoriasis with suboptimal response to 40 mg every other week dosing: results from an open-label study-Reference-Cited by-同舟云学术

Efficacy, safety and medication cost implications of adalimumab 40 mg weekly dosing in patients with psoriasis with suboptimal response to 40 mg every other week dosing: results from an open-label study

Published:2012-08-20 Issue:3 Volume:167 Page:658-667
ISSN:0007-0963
Container-title:British Journal of Dermatology
language:en
Short-container-title:

Author:

Leonardi C.,Sobell J.M.,Crowley J.J.,Mrowietz U.,Bao Y.,Mulani P.M.,Gu Y.,Okun M.M.

Publisher

Wiley

Subject

Dermatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1365-2133.2012.11041.x/fullpdf

Reference16 articles.

1. Definition of treatment goals for moderate to severe psoriasis: a European consensus;Mrowietz;Arch Dermatol Res,2011

2. Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial;Menter;J Am Acad Dermatol,2008

3. Adalimumab: in plaque psoriasis;Croom;Am J Clin Dermatol,2009

4. Classification tree analysis: a statistical tool to investigate risk factor interactions with an example for colon cancer (United States);Camp;Cancer Causes Control,2002

5. Classification and regression tree analysis in public health: methodological review and comparison with logistic regression;Lemon;Ann Behav Med,2003

Cited by 45 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effectiveness and Safety of Weekly Adalimumab for Non-Infectious Chronic Anterior Uveitis in Children;Ocular Immunology and Inflammation;2023-11-16

2. Increasing to weekly adalimumab dosing leads to improved psoriasis outcomes—A retrospective single‐centre review of real‐world data;Journal of the European Academy of Dermatology and Venereology;2022-10-10

3. Effectiveness and Safety of High‐Dose Biologics in Juvenile Idiopathic Arthritis in the Childhood Arthritis and Rheumatology Research Alliance;Arthritis Care & Research;2021-06-13

4. Certolizumab pegol in the treatment of psoriasis: Real‐life data;Dermatologic Therapy;2021-03-10

5. Comment on “Antipsoriatic treatments during COVID ‐19 outbreak”;Dermatologic Therapy;2020-06-12